RGS1 and related genes as potential targets for immunotherapy in cervical cancer: computational biology and experimental validation
Abstract Background Effective treatment is needed for advanced, inoperable, or chemotherapy-resistant cervical cancer patients. Immunotherapy has become a new treatment modality for cervical cancer patients, and there is an urgent need to identify additional targets for cervical cancer immunotherapy...
Main Authors: | Siyang Zhang, Han Wang, Jiao Liu, Tao Tao, Zhi Zeng, Min Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-07-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12967-022-03526-0 |
Similar Items
-
The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives
by: Robert J. Walsh, et al.
Published: (2021-09-01) -
Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma
by: Jinna Li, et al.
Published: (2023-08-01) -
Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions
by: Masahiro Kagabu, et al.
Published: (2020-03-01) -
Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer
by: YANG Junyuan, et al.
Published: (2022-09-01) -
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
by: Margherita Turinetto, et al.
Published: (2022-03-01)